Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is advancing a wholly owned pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Kα mutant selective program (RLY-PI3K1047 program). Relay has completed IND-enabling activities for RLY-4008, a potent and selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) and initiated a Phase 1 clinical trial for RLY-1971, a selective inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), in patients with advanced solid tumors in Q1 2020. In addition to the 3 described above, Relay has 5 discovery stage programs across precision oncology and genetic disease.